We have located links that may give you full text access.
Amentoflavone, a biflavonoid from Biophytum sensitivum augments lymphocyte proliferation, natural killer cell and antibody dependent cellular cytotoxicity through enhanced production of IL-2 and IFN-gamma and restrains serum sialic acid and gamma glutamyl transpeptidase production in tumor - bearing animals.
Modulation of immune response is highly relevant in tumor cell destruction. The present study is focused on the effect of amentoflavone, a biflavonoid from Biophytum sensitivum on cell-mediated immune responses in normal and tumor-bearing control animals. Tumor was induced in BALB/c mice by intraperitoneal injection of Ehrlich ascites carcinoma cells. Treatment of amentoflavone significantly enhanced natural killer cell activity in normal (42.8% cell lysis) and tumor bearing animals (48.2% cell lysis) on the fifth day, which was much earlier compared to tumor-bearing control animals (20.2% cell lysis on day 9). Antibody-dependent cellular cytotoxicity was also increased in amentoflavone -treated normal (41% cell lysis on day 9) and tumor bearing animals (43.8% cell lysis on day 9) compared to untreated tumor bearing control animals (maximum of 15.2% cell lysis on day 13). Amentoflavone administration could significantly enhance the mitogen-induced splenocyte, thymocyte, and bone marrow cell proliferation. Treatment of amentoflavone significantly elevated the production of interleukin-2 and interferon-gamma in normal and Ehrlich ascites carcinoma-bearing animals. Moreover amentoflavone treatment significantly reduced the elevated levels of serum sialic acid and serum gamma glutamyl transpeptidase activity in tumor bearing animals.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app